DNA Methylation Ageing Biomarkers in People With HIV: A Framework for Clinical Interpretation

People with HIV (PWH) show heterogeneous ageing trajectories shaped by both HIV-related and non-HIV factors. DNA methylation (DNAm)-derived ageing biomarkers are increasingly used in HIV research, but their clinical meaning remains uncertain. This Review considers how such findings should be interpreted in relation to clinically relevant vulnerability. Cross-sectional associations should be distinguished from longitudinal prediction, and any added predictive value should be tested against established clinical measures. Interpretation also depends on what each DNAm measure was trained to capture and on the clinical setting in which it is studied. We examine evidence relating DNAm biomarkers to frailty, physical function, physiologic risk, and clinical outcomes, with particular attention to immune status and treatment history. Current evidence supports their use as research tools rather than as individual diagnostic tests or guides to treatment.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-11-18
DOI
https://doi.org/10.1093/ofid/ofag757
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA Methylation Ageing Biomarkers in People With HIV: A Framework for Clinical Interpretation

Kazuko Yamamoto, Hideta Nakamura, Andrés Esteban-Cantos, Estebán Martínez
3 links
Open Forum Infectious Diseases
HIV-related health complications and treatments
article

DNA Methylation Ageing Biomarkers in People With HIV: A Framework for Clinical Interpretation

Kazuko Yamamoto, Hideta Nakamura, Andrés Esteban-Cantos, Estebán Martínez
article en

Abstract

People with HIV (PWH) show heterogeneous ageing trajectories shaped by both HIV-related and non-HIV factors. DNA methylation (DNAm)-derived ageing biomarkers are increasingly used in HIV research, but their clinical meaning remains uncertain. This Review considers how such findings should be interpreted in relation to clinically relevant vulnerability. Cross-sectional associations should be distinguished from longitudinal prediction, and any added predictive value should be tested against established clinical measures. Interpretation also depends on what each DNAm measure was trained to capture and on the clinical setting in which it is studied. We examine evidence relating DNAm biomarkers to frailty, physical function, physiologic risk, and clinical outcomes, with particular attention to immune status and treatment history. Current evidence supports their use as research tools rather than as individual diagnostic tests or guides to treatment.

Open Forum Infectious Diseases
Hospital Universitario La Paz (ES), Instituto de Salud Carlos III (ES), University of the Ryukyus (JP), Hospital La Paz Institute for Health Research (ES), Centro de Investigación Biomédica en Red (ES), Hospital Clínic de Barcelona (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES), Universitat de Barcelona (ES)
Good health and well-being
HIV-related health complications and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon